GBA Presents: RADIO SAVANT-!

stonedinvestor said:
NU becomes a good trade here because they report soon and they always beat their number.-

Adding more.

What happened
Nu Holdings (NU -7.83%) was dropping fast on Wednesday, as the stock price was down as much as 8.2% in the morning session. By 2 p.m. ET, it was down about 7% to $4.75 per share.

It was a bad day all around as the major indexes were all down, with the Dow Jones Industrial Average off 1.4%, the S&P 500 down 1.4%, and the Nasdaq dropping 1.8% as of 2 p.m.

So what
The overall market decline related to the unsettled U.S. elections was likely the main reason that Nu Holdings, a Brazil-based online bank, was falling today. Control of the Senate and House was still up in the air as of Wednesday afternoon, and the uncertainty spooked investors.

Another fact that may have hurt Nu was the subpar earnings report by Upstart Holdings, a fellow fintech that missed analysts' estimates and saw revenue tank on a sharp decrease in loans and a greater-than-anticipated loss per share.

GBA word-- NU is in Brazil!!! UPST haS NO baring Ditto OUR election these are BS reasons! Excuses to sell.


NU.png

NYSE: NU
Nu Holdings Ltd.
Today's Change
(-7.83%) -$0.40
Current Price
$4.71

These factors may have weighed on all fintechs, but Nu Holdings, the holding company for Nubank, operates in a completely different market, Brazil, along with other Latin American markets. It actually had some good news on Wednesday that the market didn't recognize.

OPPORTUNITY!!!!!!!


Now what
One positive development for Nu on Wednesday was an outperform rating by analysts at Credit Suisse. Credit Suisse initiated coverage of Nu Holdings with a $6.50 price target, which would be a 36% increase from current levels.

Also, Brazil's Economy Ministry came out with gross domestic product (GDP) growth estimates for 2023 and set a range of 1.4% and 2.9%. This is within the range of previous estimates of roughly 2.5% GDP growth. This year, the economy is expected to finish with 2.7% growth in GDP.

Brazil is where it's at!

Even the lower end of the GDP growth range is higher than the projected 1.1% GDP growth for the U.S. next year.

Nu Holdings has been growing rapidly as a disruptor in the Brazilian market with lower-cost digital banking services. It had record revenue in the second quarter and grew its customer base by 57% year over year last quarter.


Nu Holdings reports third-quarter earnings on Nov. 14, so investors will want to see if it continues that forward momentum.

HAND OVER FIST ALERT******* NU
More...




WHEN STONEY DOUBLES DOWN IT PAYS TO LISTEN-!

Nu Holdings reports Q3 results
Nov. 14, 2022 6:24 PM ETNu Holdings Ltd. (NU)
  • Nu Holdings press release (NYSE:NU): Q3 Adjusted Net Income of $63.1M.
  • Revenue of $1.3B beats by $120M.
  • Nu maintains significant excess liquidity with a loan-to-deposit ratio of 25%. On September 30, 2022, Nu had an interest-earning portfolio of $3.5 billion, while total deposits were four times this amount at $14.0 billion.
  • Shares +14.94% AH. :D
 
stonedinvestor said:
Ginkgo Bioworks down 7% as it sees fewer new cell programs, lower Foundry revenue range :caution:

Cathie boots another one... I like the old pictures of her a lot better, feel the same way about myself.
More...
It's $2.55...
What I say? $2.53?:rolleyes:

Speaking of penny stocks... EZFL dropped another 10% yesterday. :D
 
This is a bs article dude.
The guy doesn't know how to read a report.
That's why I tell you all the time to use your own brain and quit depending on these amateurs.

Ginkgo Bioworks down 7% as it sees fewer new cell programs, lower Foundry revenue range
Nov. 14, 2022 5:33 PM ETGinkgo Bioworks Holdings, Inc. (DNA)By: Jonathan Block, SA News Editor6 Comments


image_188076504.jpg

CharlieAJA



  • Ginkgo Bioworks (NYSE:DNA) is down ~7% in after-hours trading (DNA) after it said it plans to add 55-60 new cell programs to the Foundry platform this year. It previously projected 60.
  • The company also revised its Foundry revenue to $150M–$170M this year. The range previously was $165M-$180M.
  • Ginkgo (DNA) also updated its total revenue estimate for 2022 to $460M-$480M from $425M-$440M. Consensus to $435.31M.
  • In its Q3 2022 earnings, the company beat on the top line but missed on the bottom.
  • Its net loss widened ~553% in the quarter to ~$669M compared to Q3 2021.
  • Ginkgo (DNA) ended the quarter with ~$1.3B in cash and cash equivalents, a ~16% decline from Dec. 31, 2021.
 
Hexo, Entourage Health sign long-term supply agreement 07:39 HEXO, ETRGF HEXO (HEXO) announced the execution of a long-term supply agreement with Entourage Health (ETRGF), a Canadian producer and distributor of award-winning cannabis products. Under the Supply Agreement, HEXO will provide Entourage with bulk dried cannabis and soft gel capsules, to be marketed to patients and consumers under Entourage's family of brands. HEXO-branded products will also expand Entourage's premium product offerings available to respective patients of Starseed Medicinal and Syndicate Cannabis medical marketplaces. This strategic relationship will allow HEXO to better address the needs of Canadian medical patients through Entourage's medical channels. At the same time, Entourage will benefit from HEXO's cultivation and processing capabilities by obtaining a consistent supply of cannabis and soft gel capsules to meet Entourage's anticipated short-term demand. "We are thrilled to partner with a like-minded company that has an unparalleled understanding and dedication to delivering the highest quality cannabis products to Canadians," said Charlie Bowman, CEO of HEXO Corp. "This relationship with Entourage not only complements our growing health and wellness portfolio, but also accelerates our ability to grow the business and deliver premium cannabis products to more Canadians. Collaborating with Entourage marks a significant milestone for HEXO in the Canadian medical market and highlights our commitment to addressing the range of consumer needs and market demand. We see increasing opportunity in medicinal and therapeutic products and believe the market fits well with our high-quality products," added Bowman.
 
Paysafe launches paysafecard as alternative payment on Microsoft.com, Xbox.com 05:13 PSFE, MSFT Paysafe (PSFE) has further strengthened its relationship with Microsoft (MSFT), launching paysafecard as a new alternative payment option on Microsoft.com and Xbox.com in the United States and eight additional European countries. The ongoing collaboration between the two companies now spans 31 countries. This latest development means that millions of new customers in the U.S. and Europe who don't have access to traditional online payment solutions or who prefer not to share their credit card information online can now make cash-based purchases on Microsoft.com and Xbox.com. In 22 European countries, this service is also available on the Xbox game console. The prepaid payment solution paysafecard, available in 50 countries through a distribution network of 700,000 retail stores, enables consumers to use cash to pay for services online. Using a 16-digit code, payment transactions are completed simply and reliably. Bank account or credit card details are not required. The expanded cooperation between Paysafe and Microsoft is the newest extension of a collaboration between the two companies which first saw paysafecard offered as a payment method on Microsoft.com and Xbox.com in December 2020 and includes a multi-year, global deal for Microsoft to support Paysafe's cloud-based transaction services using Microsoft Azure.
 
This is all you need to know.
That guy's a rookie.
He needs some real world experience.
$2.60 as I type and moving up.
16M shares traded in BLOCK TRADES yesterday Stoney.
At the ask.
I doubt it goes much below $2.40 if it does drop.


vanzandt said:
Don't let that huge (headline) yoy revenue drop confuse you, the algos are reacting to that, it's an accounting thing.
They raised 2022 guidance substantially and their bio-security division was raised to $310M... at a 41% margin.

This thing should have strong support at $2.40ish

_______________________

Full Year 2022 Guidance

Ginkgo expects to add 55-60 new Cell Programs to the Foundry platform in 2022
Ginkgo further revised its expectation for Total revenue from $425 – $440 million to $460 – $480 million in 2022
Ginkgo revised its expectation for Foundry revenue to $150 – $170 million in 2022, which reflects our current assumptions and uncertainty regarding the timing of certain discrete milestone payments
While Biosecurity remains an uncertain business, based on strong year-to-date performance Ginkgo now expects Biosecurity revenue in 2022 of at least $310 million

--------------------

280 block trades today. 6M shares.
Always a good sign

Edit
That's almost a 10% increase in revenue guidance... with one quarter left?!!
Business must be pretty damn strong.

$2.57 now Stoney.
Don't miss the boat. :cool:
More...
 
You must log in or register to reply here.
Back
Top